<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00509834</url>
  </required_header>
  <id_info>
    <org_study_id>AMP IC 01-01</org_study_id>
    <nct_id>NCT00509834</nct_id>
  </id_info>
  <brief_title>A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Proven Candidaemia</brief_title>
  <acronym>SLIC</acronym>
  <official_title>A Phase-IIa, Double-blind, Randomized Study on the Tolerability and Early Efficacy of hLF1-11 in Hospitalized Patients With Proven Candidaemia. (SLIC: Study of Lactoferrin Peptide in Infections With Candida)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AM-Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AM-Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase-I, double-blind, randomized study with hLF1-11 to study the tolerability and&#xD;
      early efficacy of hLF1-11 compared to standard fluconazole therapy in hospitalized patients&#xD;
      with invasive Candida infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RATIONALE FOR THE STUDY&#xD;
&#xD;
      Choice of Drug&#xD;
&#xD;
      Fluconazole is considered &quot;standard care&quot; for the treatment of Candida infections, including&#xD;
      candidaemia in hospitalized patients.&#xD;
&#xD;
      Preclinical data has demonstrated that hLF1-11 possesses potent antimycotic effects against&#xD;
      Candida sp and, importantly, to be synergistic with fluconazole, whereby Candida strains that&#xD;
      are fluconazole-resistant become sensitive through the addition of hLF1-11&#xD;
&#xD;
      Choice of Patient Population&#xD;
&#xD;
      Based on preclinical data hLF1-11 has been shown to possess potent effects on Candida&#xD;
      albicans models in vitro and in vivo. Furthermore, candidaemia (bloodstream Candida&#xD;
      infection) is one of the most likely settings to elicit a therapeutic response since the&#xD;
      product is presented as an intravenous formulation&#xD;
&#xD;
      As previously mentioned, fluconazole and hLF1-11 exhibit a synergistic effect in preclinical&#xD;
      studies, whereby the effect of fluconazole is enhanced by the addition of hLF1-11.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Patient population not available&#xD;
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">January 2009</completion_date>
  <primary_completion_date type="Anticipated">January 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Haematology, biochemistry, and microbiological evaluation Adverse event monitoring.</measure>
    <time_frame>28 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Test of Cure (TOC): Clinical: complete resolution of clinical signs and symptoms or resolution to a point where no further antifungal therapy is judged necessary; and Microbiological: eradication of Candida identified at baseline.</measure>
    <time_frame>28 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Candidaemia</condition>
  <arm_group>
    <arm_group_label>hLF1-11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hLF1-11 0.5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo formulation is Similar to hLF1-11 iv formulation except for the active component</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hLF1-11</intervention_name>
    <description>The study treatment consists of IV administration of:&#xD;
(A) hLF1-11 (0.5mg IV bolus daily for 14 days) + fluconazole (up to 1g IV four times daily; 14 days): Group #1, n=10; OR (B) Fluconazole (up to 1g IV four times daily; 14 days) + matching placebo for hLF1-11: Group #2, n=10</description>
    <arm_group_label>hLF1-11</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hLF1-11</intervention_name>
    <description>0.5mg hLF1-11 iv per day for 14 consecutive days</description>
    <arm_group_label>hLF1-11</arm_group_label>
    <other_name>human lactoferrin 1-11</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent must be obtained before admission in the study.&#xD;
&#xD;
          -  Patients in whom Candida species have been confirmed by 2 consecutive blood cultures&#xD;
             within 12 hours.&#xD;
&#xD;
          -  Patients who have not received systemic administration of antifungal agents or who&#xD;
             have started such administration within 48 hours prior to entry.&#xD;
&#xD;
          -  Patients who have hepatic and renal parameters within 2X ULN (upper level of&#xD;
             normality) at screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history of hypersensitivity to fluconazole or hLF1-11.&#xD;
&#xD;
          -  Patients who have been treated with fluconazole for at least 1 week within the&#xD;
             previous 4 weeks.&#xD;
&#xD;
          -  Patients with a history of fluconazole-resistant Candida species within 12 weeks.&#xD;
&#xD;
          -  Neutropenic patients with neutrophil count below 0.5x10^9/L.&#xD;
&#xD;
          -  Patients who are treated with terfenadine, triazolam, cisapride, and ergotamine, which&#xD;
             are contraindicated for concomitant use with fluconazole.&#xD;
&#xD;
          -  Patients known to have AIDS or who are HIV-positive.&#xD;
&#xD;
          -  Females who have a positive pregnancy test at baseline or are capable of child-bearing&#xD;
             i.e. without appropriate contraception (chemical or mechanical).&#xD;
&#xD;
          -  Patients with suspected candida osteomyelitis, endocarditis, or meningitis.&#xD;
&#xD;
          -  Patients who have received an investigational drug within three months prior to the&#xD;
             study.&#xD;
&#xD;
          -  Patients with a concomitant medical condition, in whom, in the opinion of the&#xD;
             Investigator, participation may create an unacceptable risk for the patient.&#xD;
&#xD;
          -  Patients considered inappropriate by the PI for enrollment in the study, for any&#xD;
             reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Professor P.E. Verweij, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC St. Radboud, Nijmegen, The Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UMC St. Radboud</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>July 31, 2007</study_first_submitted>
  <study_first_submitted_qc>July 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2007</study_first_posted>
  <last_update_submitted>June 29, 2015</last_update_submitted>
  <last_update_submitted_qc>June 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hLF1-11</keyword>
  <keyword>Candida</keyword>
  <keyword>candidaemia</keyword>
  <keyword>lactoferrin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactoferrin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

